Pelthos Therapeutics Q3 EPS Decreased by HC Wainwright

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for Pelthos Therapeutics in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($4.60) per share for the quarter, down from their prior forecast of ($3.27). The consensus estimate for Pelthos Therapeutics’ current full-year earnings is ($13.25) per share. HC Wainwright also issued estimates for Pelthos Therapeutics’ Q4 2026 earnings at ($4.71) EPS, FY2027 earnings at ($7.76) EPS, FY2028 earnings at $3.16 EPS, FY2029 earnings at $7.22 EPS and FY2030 earnings at $10.23 EPS.

Separately, Oppenheimer decreased their target price on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $55.40.

Pelthos Therapeutics Trading Down 5.8%

Shares of PTHS opened at $25.90 on Tuesday. The company has a current ratio of 1.98, a quick ratio of 1.31 and a debt-to-equity ratio of 3.40. The firm has a 50-day moving average price of $27.48 and a 200 day moving average price of $25.14. Pelthos Therapeutics has a 12-month low of $18.19 and a 12-month high of $37.50. The firm has a market capitalization of $99.20 million, a P/E ratio of -1.18 and a beta of 3.10.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%.The company had revenue of $15.60 million for the quarter.

Institutional Trading of Pelthos Therapeutics

Several hedge funds have recently made changes to their positions in PTHS. Persistent Asset Partners Ltd boosted its stake in shares of Pelthos Therapeutics by 150.0% in the fourth quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after purchasing an additional 3,604 shares during the period. Pale Fire Capital SE boosted its position in Pelthos Therapeutics by 59.5% in the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after buying an additional 4,819 shares during the period. Millennium Management LLC acquired a new position in shares of Pelthos Therapeutics in the fourth quarter worth $343,000. Geode Capital Management LLC increased its position in shares of Pelthos Therapeutics by 31.9% during the fourth quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock worth $422,000 after acquiring an additional 3,295 shares during the period. Finally, Knott David M Jr increased its position in shares of Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after acquiring an additional 1,792 shares during the period. Institutional investors and hedge funds own 77.96% of the company’s stock.

Insider Buying and Selling at Pelthos Therapeutics

In related news, Director Todd C. Davis purchased 35,948 shares of Pelthos Therapeutics stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $27.82 per share, with a total value of $1,000,073.36. Following the purchase, the director owned 75,834 shares of the company’s stock, valued at approximately $2,109,701.88. The trade was a 90.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold 1,638 shares of company stock worth $43,107 in the last ninety days. 12.70% of the stock is owned by company insiders.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).